Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of “Hold” by Analysts

Shares of Prothena Corporation plc (NASDAQ:PRTA) have been given an average rating of “Hold” by the ten analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.50.

A number of research firms recently issued reports on PRTA. Chardan Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Prothena in a research note on Thursday, August 28th. JMP Securities lowered their target price on shares of Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Tuesday, September 2nd. Cantor Fitzgerald restated a “neutral” rating on shares of Prothena in a research report on Friday, June 20th. HC Wainwright raised their price target on shares of Prothena from $14.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prothena in a research report on Saturday, September 27th.

Institutional Trading of Prothena

Several hedge funds and other institutional investors have recently bought and sold shares of PRTA. Prospera Financial Services Inc acquired a new stake in Prothena in the 2nd quarter worth $61,000. GAMMA Investing LLC lifted its holdings in Prothena by 4,626.0% during the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 5,875 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Prothena by 571.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 10,815 shares during the last quarter. Corton Capital Inc. bought a new position in Prothena during the 2nd quarter valued at about $85,000. Finally, Los Angeles Capital Management LLC bought a new position in Prothena during the 2nd quarter valued at about $101,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Trading Up 3.1%

NASDAQ:PRTA opened at $10.17 on Friday. Prothena has a 1 year low of $4.32 and a 1 year high of $18.88. The firm’s fifty day simple moving average is $8.40 and its 200 day simple moving average is $7.93. The firm has a market capitalization of $547.45 million, a PE ratio of -1.80 and a beta of -0.11.

Prothena (NASDAQ:PRTA) last posted its earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.75). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The firm had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. As a group, analysts anticipate that Prothena will post -4.04 EPS for the current fiscal year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.